HRV Global Life Sciences and Shodhana Laboratories have entered into a transformative partnership aimed at advancing high-science active pharmaceutical ingredient (API) development. This collaboration stands out as HRV becomes the first integrated virtual API and pharmtech company in India to establish a strategic contract development and manufacturing agreement with Shodhana Laboratories, a reputable Hyderabad-based API manufacturer that aligns with US FDA standards.
Innovative API Development
This multi-year agreement focuses on co-developing, manufacturing, and supplying an exclusive pipeline of high-science APIs. These pharmaceutical-grade APIs emphasize longevity biology and are supported by a US Drug Master File (DMF). Notably, HRV now holds the only active Indian DMF for this category, highlighting its pioneering role in the industry.
Merging Expertise for Success
The collaboration unites HRV’s extensive global market access across more than 50 countries with Shodhana’s deep expertise in process chemistry and high-purity synthesis. This combination creates a streamlined pathway from development to commercialization for cutting-edge molecules in precision medicine. Such synergy not only enhances the quality of the products but also accelerates their entry into the market.
Comprehensive Development Strategy
Under the terms of the partnership, both companies will collaborate on the development and US DMF filing for a master coenzyme. This molecule plays a crucial role in cellular energy, DNA repair, and aging, and is emerging as a regulated therapeutic API within oncology, neurodegeneration, and longevity medicine. The partnership aims to develop a total of five high-science APIs that address crucial areas such as central nervous system disorders, rare or orphan diseases, and metabolic or neurological conditions.
Regulatory Excellence and Quality Assurance
The companies ensure end-to-end compliance with Good Manufacturing Practices (GMP) and maintain robust chemistry, manufacturing, and controls (CMC) documentation. They adhere to stability studies and validation standards aligned with US FDA, EMA, PMDA, and ANVISA regulations. HRV is responsible for managing all regulatory interactions and associated expenses, which streamlines the process and reinforces the partnership’s commitment to quality.
Strategic Leadership Insights
Hari Kiran Chereddi, MD & CEO of HRV Global Life Sciences, emphasizes the significance of this development, stating that the API launch signifies the emergence of a new pharmaceutical category rather than merely a wellness trend. He believes that the partnership’s synthesis precision and global regulatory platform will allow Indian manufacturing to meet the high standards required for drug development.
Nikhil Thota, Director of Shodhana Laboratories, echoes this sentiment by highlighting the necessity for synthesis precision and quality systems in producing pharmaceutical-grade APIs. He expresses confidence that the partnership with HRV will enhance Shodhana’s visibility and establish its reputation in high-science API manufacturing on a global scale.
Milestone-Gated Framework for Development
The partnership has already initiated five active development programs, with both organizations collaborating on regulatory strategy and documentation. This structured, milestone-gated framework ensures a systematic approach to achieving their objectives and reinforces HRV’s vision of creating an AI-enabled, asset-light pharmaceutical platform.
Conclusion
The alliance between HRV Global Life Sciences and Shodhana Laboratories positions both companies at the forefront of high-science API development. With a focus on precision medicine and rigorous regulatory compliance, they are set to redefine the landscape of pharmaceutical manufacturing. This innovative partnership not only showcases India’s capabilities in the global API market but also paves the way for future advancements in drug development.
- HRV Global Life Sciences and Shodhana Laboratories form a strategic partnership for API development.
- The partnership focuses on high-science APIs for longevity biology and precision medicine.
- HRV holds the only active Indian DMF for pharmaceutical-grade APIs.
- Both companies emphasize rigorous regulatory compliance and quality assurance in manufacturing.
- The collaboration has already launched five active development programs under a structured framework.
Read more → www.pharmabiz.com